UDG HEALTHCARE PLC

INTERIM MANAGEMENT STATEMENT

4 February 2014: UDG Healthcare plc (“the Group”), a leading international provider of healthcare services, provides the following Interim Management Statement covering the period from 1 October 2013 to the date of this announcement.

Quarter to 31 December 2013

Group

Performance for the quarter to 31 December 2013 has been satisfactory. Group revenues for the three months, measured on a constant currency basis, are ahead of the same period last year. As anticipated, reported profitability for the first quarter is below last year’s levels, mainly due to the incremental financing costs associated with the September 2013 private debt placement and the one-off divisional re- branding costs, both of which are weighted towards the first half of the year.

Each of the three divisions made good progress during the period.

Ashfield Commercial and Medical Services

The division is a global leader in the provision of contract sales outsourcing (CSO) and associated services to pharmaceutical manufacturers with operations in major markets including continental Europe, the UK, North America and a presence in South America and Asia. Trading during the period has been strong with revenues and profits well ahead of the same period last year.

Over the past six months we have acquired the MCG and Expansis businesses in Canada and Spain respectively and have merged them with our existing CSO businesses in line with plan. This will generate operating synergies and will make us market leader in both markets. Our other European businesses continue to perform well and are consistently improving their performance through business development, margin expansion and tight cost control.

In 2012, we entered a joint arrangement in Japan to provide CSO services in the second largest pharmaceutical market in the world. This business continues to perform ahead of plan and is expected to become profitable in the second half of this year.

Our Healthcare Communications business continues to win business and to trade well, and has consistently produced higher margins than the rest of the division.

Trading across the division overall continues to be strong with the more mature UK market performing well and the US business continuing to deliver very strong growth. The progress in this division leaves us increasingly confident of achieving our medium term target of a 10% operating margin for this division.

Supply Chain Services

The division provides logistics services to healthcare companies, pharmacies and hospitals in the UK and Ireland. Trading during the period has been good with revenues ahead of the same period last year, although profits have been lower, mainly due to the sales mix favouring the lower margin businesses.

Our United Drug wholesale business in the Republic of Ireland and Northern Ireland traded well and has continued to gain market share in the declining Republic of Ireland market. We have also recently completed a significant automation programme in our Dublin warehouse, that when fully optimised will enable us to service the market more efficiently.

Our United Drug pre-wholesale business traded well in the period and continues to strengthen its market leading position through new business wins both in Ireland and in our UK joint venture.

First quarter profits in our Aquilant Medical and Scientific business were lower than in the same period last year, although the timing of orders and recent business wins should deliver strong trading for the remainder of the year.

Our pharmaceutical “specials” business provides niche medicines to retail and hospital pharmacies in the UK. As we have previously indicated, over the past two years, this market has been impacted by the introduction of a drug tariff on the most popular products in this market. The business performed on budget for the first quarter as a result of better market conditions and its cost reduction programme.

Sharp Packaging Services

The division is a leading international provider of commercial and clinical trial pharmaceutical packaging services with facilities in the US, UK, Dutch and Belgian markets. Trading during the period has been in-line with expectations, although behind the particularly strong performance in the first quarter of last year.

Sharp US continues to win business in a market that is seeing an increased demand for top quality outsourced packaging services. Our order pipeline in the US is strong for the remainder of the year.

The “Drug Quality and Safety Act” was signed into US law by President Obama in late November 2013. This will place a new requirement for each package of medicine to have a unique serialisation number by January 2017, which can then be tracked throughout the supply chain. We believe that serialisation will be a key driver of future growth in the outsourced packaging industry globally as similar requirements are being introduced in Europe and other markets. We are investing significant time and resources working with existing and potential clients to prepare for this change.

The first phase of the capacity expansion programme at our Allentown facility in Pennsylvania has now been completed and this will provide 10% extra packaging capacity for our clients in Sharp US.

Sharp Europe has traded ahead of its performance level in the second half of 2013. The UK commercial packaging plant ceased production in December, and we anticipate that the Sharp Europe business will breakeven for the second half of this year.

Outlook

Based on the underlying trading performance for the year to date and the outlook for the remainder of the year, the Group expects constant currency adjusted diluted earnings per share (EPS) for the year to 30 September 2014, before amortisation of acquired intangible assets and acquisition costs, to be between 2% and 5% ahead of last year. We expect that this result will be weighted towards the second half of the year. Excluding the increased private placement financing costs and the one-off re- branding costs noted above, underlying EPS growth for the year is expected to be 8% to 11%.

The Group also expects to deliver another good cash flow performance in the year, although this will be weighted towards the second half of the year due to the timing of cash inflows. When combined with modest debt levels relative to earnings and significant financing facilities, this leaves the Group well positioned to support its future growth objectives both organically and through acquisition.

Conference Call

UDG Healthcare plc will host a conference call for investors and analysts at 8.30am (GMT) today, 4 February 2014 to discuss this statement. The dial-in details are as follows:

Standard International Access +44 (0) 20 3003 2666 UK Toll Free 0808 109 0700 Ireland +353 (0) 1 436 0959 Password UDG Healthcare

A playback facility will be available for seven days on +44 (0) 20 8196 1998 (UK) or + 353 (0) 1 486 4035 (Ireland) or +44 (0) 20 8196 1998 (International). The access code for the replay will be 6319277.

2014 Reporting Timetable

The Group will issue interim results for the six months to 31 March 2014 on Wednesday 14 May, 2014.

Forward Looking Statements

This Statement contains certain forward-looking statements. They represent expectations for the Group’s business, and involve risks and uncertainties. The Group has based these forward-looking statements on current expectations and projections about future events. The Group believes that expectations and assumptions with respect to these forward-looking statements are reasonable. However, because they involve known and unknown risks, uncertainties and other factors, which in some cases are beyond the Group’s control, actual results or performance may differ materially from those expressed or implied by such forward- looking statements.

ENDS

For reference:

Investors and Analysts: Liam FitzGerald Alan Ralph UDG Healthcare plc UDG Healthcare plc Tel: +353-1-463-2300 Tel: + 353-1-463-2300

Media: Greg Lawless / Lisa Kavanagh / Claire Turvey Powerscourt Tel: +44-207-250-1446

About UDG Healthcare plc:

Listed on the London Stock Exchange, UDG Healthcare plc is a leading international provider of services to healthcare manufacturers and pharmacies, with operations in 22 countries including the US, UK, Ireland and Germany.

UDG Healthcare plc operates across three divisions: Ashfield Commercial and Medical Services, Supply Chain Services and Sharp Packaging Services.

Ashfield Commercial and Medical Services is a global leader in the provision of contract sales outsourcing services to pharmaceutical manufacturers with operations in major markets including continental Europe, the UK, North America and a presence in South America and Asia. The division provides sales teams, telesales, nurse educators, medical information, healthcare communications and event management services to healthcare companies in 22 countries. It focuses on supporting healthcare professionals and patients at all stages of the product life cycle.

Supply Chain Services includes the United Drug Supply Chain Services and the Aquilant Specialist Healthcare Services businesses. United Drug Supply Chain Services is the largest pharmaceutical wholesaler in the island of Ireland. It is also the leading pre-wholesaler in Ireland and has achieved the No.1 position in the UK through its joint venture business UniDrug Distribution Group. The division provides logistics services to healthcare companies, pharmacies and hospitals in the UK and Ireland. Aquilant Specialist Healthcare Services is a leading provider of outsourced sales, marketing, distribution and engineering services to the medical and scientific sectors in Ireland and the UK.

Sharp Packaging Services is a leading international provider of pharmaceutical contract packaging and clinical trials materials services with facilities in the US, UK, Dutch and Belgian markets.

For more information go to: www.udghealthcare.com